Sun Pharmaceutical Industries Ltd Stock Price Today (NSE: SUNPHARMA)
Fundamental Score
Sun Pharmaceutical Industries Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Sun Pharmaceutical Industries Ltd share price today is ₹1717.10, up +0.00% on NSE/BSE as of 17 February 2026. Sun Pharmaceutical Industries Ltd (SUNPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹4.34L (Cr). The 52-week high for SUNPHARMA share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 37.57x, SUNPHARMA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 16.86% and a debt-to-equity ratio of 0.07.
Sun Pharmaceutical Industries Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Sun Pharmaceutical Industries Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Sun Pharmaceutical Share Price: A Financial Analysis
The pharmaceutical industry is experiencing a period of intense innovation, driven by advancements in biotechnology and personalized medicine. This is significantly impacting company valuations and investment strategies. This analysis examines the financial standing of Sun Pharmaceutical Industries Ltd, focusing on key metrics that influence its industry dominance. Currently, the Sun Pharmaceutical share price stands at ₹1695.099976. The company's Price-to-Earnings (PE) ratio is 37.57, indicating the price investors are willing to pay for each rupee of earnings.
The PE ratio is a crucial benchmark for assessing relative valuation. When contrasting Sun Pharmaceutical Industries Ltd with sector peers like
Mankind Pharma Ltd, differences in PE can reflect varying market perceptions of growth potential and risk. A high PE, such as Sun Pharma's, could suggest investor optimism, but warrants further investigation into the factors justifying such a premium. Differences in management quality can also significantly impact PE ratios. How a company is run has a great impact on stock price.A critical aspect of Sun Pharma's financial strength is its Return on Capital Employed (ROCE) of 20.21%. This metric reveals how effectively the company is utilizing its capital to generate profits. A high ROCE, like Sun Pharma's, directly contributes to a strong economic moat. This indicates that the company is able to generate profits at a higher than average rate for the amount of capital employed, which then acts as a form of "barrier to entry" protecting it from other competition.
This financial analysis of Sun Pharmaceutical Industries Ltd is based on publicly available data and aims to provide an observational overview of its current financial position. This is an excerpt from a comprehensive 80-parameter fundamental audit verified by Sweta Mishra, designed to evaluate the company's long-term sustainability and competitive advantage within the pharmaceutical landscape. This analysis doesn't give any buy or sell recommendations and should not be taken as such.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Sun Pharmaceutical Industries Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SUNPHARMA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (16.86%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.21%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (26.95%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (23.78% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (23.78% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.07)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (57.54x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹37510.74 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.48%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 36.67%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
0 factors identified
No significant concerns identified in current analysis.
Sun Pharmaceutical Industries Ltd Financial Statements
Comprehensive financial data for Sun Pharmaceutical Industries Ltd including income statement, balance sheet and cash flow
About SUNPHARMA (Sun Pharmaceutical Industries Ltd)
Sun Pharmaceutical Industries Ltd (SUNPHARMA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹4.34L (Cr). Sun Pharmaceutical Industries Ltd has delivered a Return on Equity (ROE) of 16.86% and a ROCE of 20.21%. The debt-to-equity ratio stands at 0.07, reflecting the company's capital structure. Investors tracking SUNPHARMA share price can monitor key metrics including P/E ratio, promoter holding of 54.48%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
Latest News
SUNPHARMA Share Price: Frequently Asked Questions
What is the current share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA)?
As of 17 Feb 2026, 10:24 am IST, Sun Pharmaceutical Industries Ltd share price is ₹1717.10. The SUNPHARMA stock has a market capitalisation of ₹4.34L (Cr) on NSE/BSE.
Is SUNPHARMA share price Overvalued or Undervalued?
SUNPHARMA share price is currently trading at a P/E ratio of 37.57x, compared to the industry average of 31.77x. Based on this relative valuation, the Sun Pharmaceutical Industries Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of SUNPHARMA share price?
The 52-week high of SUNPHARMA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Sun Pharmaceutical Industries Ltd share price?
Key factors influencing SUNPHARMA share price include quarterly earnings growth (Sales Growth: 8.93%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sun Pharmaceutical Industries Ltd a good stock for long-term investment?
Sun Pharmaceutical Industries Ltd shows a 5-year Profit Growth of 23.78% and an ROE of 16.86%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.07 before investing in SUNPHARMA shares.
How does Sun Pharmaceutical Industries Ltd compare with its industry peers?
Sun Pharmaceutical Industries Ltd competes with major peers in the Pharmaceuticals. Investors should compare SUNPHARMA share price P/E of 37.57x and ROE of 16.86% against the industry averages to determine competitive standing.
What is the P/E ratio of SUNPHARMA and what does it mean?
SUNPHARMA share price has a P/E ratio of 37.57x compared to the industry average of 31.77x. Investors pay ₹38 for every ₹1 of annual earnings.
How is SUNPHARMA performing according to Bull Run's analysis?
SUNPHARMA has a Bull Run fundamental score of 65.2/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does SUNPHARMA belong to?
SUNPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sun Pharmaceutical Industries Ltd share price.
What is Return on Equity (ROE) and why is it important for SUNPHARMA?
SUNPHARMA has an ROE of 16.86%, which indicates excellent management efficiency. ROE measures how efficiently Sun Pharmaceutical Industries Ltd generates profits from shareholders capital.
How is SUNPHARMA debt-to-equity ratio and what does it indicate?
SUNPHARMA has a debt-to-equity ratio of 0.07, which indicates conservative financing with low financial risk.
What is SUNPHARMA dividend yield and is it a good dividend stock?
SUNPHARMA offers a dividend yield of 0.89%, meaning you receive ₹0.89 annual dividend for every ₹100 invested in Sun Pharmaceutical Industries Ltd shares.
How has SUNPHARMA share price grown over the past 5 years?
SUNPHARMA has achieved 5-year growth rates of: Sales Growth 9.87%, Profit Growth 23.78%, and EPS Growth 23.78%.
What is the promoter holding in SUNPHARMA and why does it matter?
Promoters hold 54.48% of SUNPHARMA shares, with 0.97% pledged. High promoter holding often indicates strong management confidence in Sun Pharmaceutical Industries Ltd.
What is SUNPHARMA market capitalisation category?
SUNPHARMA has a market capitalisation of ₹433739 crores, placing it in the Large-cap category.
How volatile is SUNPHARMA stock?
SUNPHARMA has a beta of N/A. A beta > 1 suggests the Sun Pharmaceutical Industries Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is SUNPHARMA operating profit margin trend?
SUNPHARMA has a 5-year average Operating Profit Margin (OPM) of 26.95%, indicating the company's operational efficiency.
How is SUNPHARMA quarterly performance?
Recent quarterly performance shows Sun Pharmaceutical Industries Ltd YoY Sales Growth of 8.93% and YoY Profit Growth of 2.56%.
What is the institutional holding pattern in SUNPHARMA?
SUNPHARMA has FII holding of 16.55% and DII holding of 20.12%. Significant institutional holding often suggests professional confidence in the Sun Pharmaceutical Industries Ltd stock.